# Finerenone and Empagliflozin Combination in Obesity With Hypertension: A 12-Week Prospective, Parallel-design, Double-blind, Randomized, Placebo-controlled Trial

> **NCT07678151** · NA · NOT_YET_RECRUITING · sponsor: **Heart Health Research Center** · enrollment: 260 (estimated)

## Conditions studied

- Hypertension (HTN)

## Interventions

- **DRUG:** Empagliflozin and Finerenone
- **DRUG:** Placebo for Empagliflozin and Finerenone

## Key facts

- **NCT ID:** NCT07678151
- **Lead sponsor:** Heart Health Research Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-13
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-08-31
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2026-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07678151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07678151, "Finerenone and Empagliflozin Combination in Obesity With Hypertension: A 12-Week Prospective, Parallel-design, Double-blind, Randomized, Placebo-controlled Trial". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07678151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*